Abstract
An elevated risk of cardiovascular events is present in patients with mild-to-moderate renal function impairment. Similar to patients with end-stage renal disease, this elevated risk can be accounted for by high prevalence of classic and emergent cardiovascular risk factors and additional conditions that are more specifically related to the organ failure, such as anemia and electrolyte disturbances. Among emergent cardiovascular risk factors, insulin resistance has been demonstrated to contribute significantly to the cardiovascular risk in the general population and it is known that abnormalities of glucose metabolism and hyperinsulinemia due to insulin resistance are present in patients with renal failure. Because patients with more advanced disease stage have several abnormalities that might affect the cellular action of insulin acting as important confounders, the relationship between insulin sensitivity and renal function should be better evaluated in the early stages of renal failure. This article overviews the evidence supporting the presence of increased cardiovascular morbidity and mortality in patients with early stages of renal disease, and examines the potential for insulin resistance to contribute to cardiovascular risk in these patients.
Keywords: Endothelial cells, Euglycemic-hyperinsulinemic clamp, Glomerular filtration rate, HOMA index, Hyperinsulinemia, Insulin receptor, electrolyte disturbances, hyperinsulinemia, cardiovascular morbidity, insulin resistance
Current Diabetes Reviews
Title:Insulin Resistance in the Early Stages of Renal Failure: Implications for Cardiovascular Risk
Volume: 8 Issue: 4
Author(s): Catena Cristiana, GianLuca Colussi, Stefania Fedrizzi and Leonardo A. Sechi
Affiliation:
Keywords: Endothelial cells, Euglycemic-hyperinsulinemic clamp, Glomerular filtration rate, HOMA index, Hyperinsulinemia, Insulin receptor, electrolyte disturbances, hyperinsulinemia, cardiovascular morbidity, insulin resistance
Abstract: An elevated risk of cardiovascular events is present in patients with mild-to-moderate renal function impairment. Similar to patients with end-stage renal disease, this elevated risk can be accounted for by high prevalence of classic and emergent cardiovascular risk factors and additional conditions that are more specifically related to the organ failure, such as anemia and electrolyte disturbances. Among emergent cardiovascular risk factors, insulin resistance has been demonstrated to contribute significantly to the cardiovascular risk in the general population and it is known that abnormalities of glucose metabolism and hyperinsulinemia due to insulin resistance are present in patients with renal failure. Because patients with more advanced disease stage have several abnormalities that might affect the cellular action of insulin acting as important confounders, the relationship between insulin sensitivity and renal function should be better evaluated in the early stages of renal failure. This article overviews the evidence supporting the presence of increased cardiovascular morbidity and mortality in patients with early stages of renal disease, and examines the potential for insulin resistance to contribute to cardiovascular risk in these patients.
Export Options
About this article
Cite this article as:
Cristiana Catena, Colussi GianLuca, Fedrizzi Stefania and A. Sechi Leonardo, Insulin Resistance in the Early Stages of Renal Failure: Implications for Cardiovascular Risk, Current Diabetes Reviews 2012; 8 (4) . https://dx.doi.org/10.2174/157339912800840532
DOI https://dx.doi.org/10.2174/157339912800840532 |
Print ISSN 1573-3998 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6417 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Neonatal Persistent Pulmonary Hypertension Associated with Congenital Cystic Adenomatoid Malformation Treated with Sildenafil: Case Report
Current Pediatric Reviews Impact of Pulmonary Vascular Resistances in Heart Transplantation for Congenital Heart Disease
Current Cardiology Reviews The Innovations in Pulmonary Hypertension Pathophysiology and Treatment: What are our Options!
Current Respiratory Medicine Reviews Alveolar Capillary Dysplasia: A Lethal Developmental Lung Malformation
Current Respiratory Medicine Reviews Nonalcoholic Fatty Liver Disease and Cardiovascular Disease
Current Pharmaceutical Design Conjugation of Resveratrol with RGD and KGD Derivatives
Protein & Peptide Letters The Role of Integrin-Mediated Cell Adhesion in Atherosclerosis: Pathophysiology and Clinical Opportunities
Current Pharmaceutical Design Dietary Nitrite in Nitric Oxide Biology: A Redox Interplay with Implications for Pathophysiology and Therapeutics
Current Drug Targets Editorial [Hot Topic:The Metabolic Treatment of Coronary Artery Disease and Heart Failure(Executive Editor: Pericle Di Napoli)]
Current Pharmaceutical Design P2Y12 Receptor Antagonists in Acute Coronary Syndrome: Clinical Implications of Pharmacologic and Pharmacogenetic Differences
Recent Patents on Cardiovascular Drug Discovery Apoptosis in COPD
Current Respiratory Medicine Reviews Critical Illness in the Obese Patient
Current Respiratory Medicine Reviews Efficacy and Cardiovascular Safety of Alpha Glucosidase Inhibitors
Current Drug Safety Plasma-Activated Solutions for Bacteria and Biofilm Inactivation
Current Bioactive Compounds A Review on Cellular and Molecular Mechanisms Linked to the Development of Diabetes Complications
Current Diabetes Reviews Atrial Fibrillation in Acute St-Elevation Myocardial Infarction: Clinical and Prognostic Features
Current Cardiology Reviews Polyunsaturated Fatty Acids and Cardiovascular Disease
Current Pharmaceutical Design Phytochemicals: Potential in Management of Climacteric Neurobiology
Current Pharmaceutical Design Polypharmacological Properties and Therapeutic Potential of β-Caryophyllene: A Dietary Phytocannabinoid of Pharmaceutical Promise
Current Pharmaceutical Design The Application of Rational Design on Phospholipase A2 Inhibitors
Current Medicinal Chemistry